JP2024543452A - プロテインチロシンホスファターゼ阻害剤及びその使用方法 - Google Patents

プロテインチロシンホスファターゼ阻害剤及びその使用方法 Download PDF

Info

Publication number
JP2024543452A
JP2024543452A JP2024527750A JP2024527750A JP2024543452A JP 2024543452 A JP2024543452 A JP 2024543452A JP 2024527750 A JP2024527750 A JP 2024527750A JP 2024527750 A JP2024527750 A JP 2024527750A JP 2024543452 A JP2024543452 A JP 2024543452A
Authority
JP
Japan
Prior art keywords
methyl
fluoro
dihydro
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543452A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー ボグダン
エリオット ピー. ファーニー
ジェニファー エム. フロスト
フィリップ アール. キム
チャオミン ション
ナオミ アン バートン
クレール アン マリー キャリオー-マムフォード
クリストファー パトリック マクマホン
ジュゼッペ ナノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2024543452A publication Critical patent/JP2024543452A/ja
Publication of JP2024543452A5 publication Critical patent/JP2024543452A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024527750A 2021-11-11 2022-11-10 プロテインチロシンホスファターゼ阻害剤及びその使用方法 Pending JP2024543452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278339P 2021-11-11 2021-11-11
US63/278,339 2021-11-11
PCT/US2022/049584 WO2023086498A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024543452A true JP2024543452A (ja) 2024-11-21
JP2024543452A5 JP2024543452A5 (cg-RX-API-DMAC7.html) 2025-11-17

Family

ID=84689141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527750A Pending JP2024543452A (ja) 2021-11-11 2022-11-10 プロテインチロシンホスファターゼ阻害剤及びその使用方法

Country Status (8)

Country Link
US (1) US20250019374A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430038A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543452A (cg-RX-API-DMAC7.html)
CN (1) CN118525016A (cg-RX-API-DMAC7.html)
AU (1) AU2022387106A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236854A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005658A (cg-RX-API-DMAC7.html)
WO (1) WO2023086498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121487923A (zh) * 2023-07-28 2026-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.

Also Published As

Publication number Publication date
CN118525016A (zh) 2024-08-20
AU2022387106A1 (en) 2024-05-23
US20250019374A1 (en) 2025-01-16
EP4430038A1 (en) 2024-09-18
WO2023086498A1 (en) 2023-05-19
MX2024005658A (es) 2024-08-06
CA3236854A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7441264B2 (ja) Jakファミリーのキナーゼの阻害剤としてのイミダゾピロロピリジン
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
EP3455204B1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
US10233186B2 (en) Inhibitors of activin receptor-like kinase
US10202388B2 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
US20250019374A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
CN111448199A (zh) 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
WO2020103884A1 (en) Cyclic Ureas
AU2023204118A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
CN114685531B (zh) 四并环化合物及其药物组合物和应用
CN105517547A (zh) 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
WO2021161105A1 (en) P2x3 modulators
JP2022514437A (ja) 治療用化合物
WO2017134555A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3707136B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
IL295196A (en) macrocyclic rip2-kinase inhibitors
US20250320185A1 (en) Aminoheteroaryl kinase inhibitors
CA3258870A1 (en) Substituted pyridinone compounds used as CBL-B inhibitors
JP2024543451A (ja) プロテインチロシンホスファターゼ阻害剤及びその使用方法
WO2024220453A1 (en) Pyrrolidinone urea fpr2 agonists
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260721